Conference Report

Clinical Update on the Treatment of Esophageal and Stomach Cancers

Source: CCO Independent Conference Coverage of the 2007 Gastrointestinal Cancers Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Clinical Update on the Treatment of Esophageal and Stomach Cancers

Faculty:
David H. Ilson, MD, PhD Joel E. Tepper, MD

CME CREDIT INFORMATION

Release Date: 05/04/07

Expiration Date: 05/03/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Specify the latest diagnostic tools for staging esophageal and stomach cancers and gauging the response to therapy
Discuss recent data from clinical studies of approved and investigational treatments for esophageal and stomach cancers
Describe the use of predictive biomarkers for patients with esophageal and stomach cancers

Topics covered include:

Introduction
Utility of PET Scanning for Preoperative Staging of Gastric Cancers
Utility of PET Scanning for Gauging the Response to Induction Chemotherapy
Identifying Predictive Biomarkers for Response to Gastric Cancer Chemotherapy
MUNICON-1: Utility of PET Scanning for Making Treatment Decisions Based on Response to Induction Chemotherapy
Correlation Between the Ratio of Positive-to-Examined Lymph Nodes and Esophageal/GEJ Cancer Prognosis
Correlation Between Gastrointestinal Stromal Tumor Bulk and Imatinib Efficacy
S-1 Adjuvant Therapy Following Curative D2 Gastrectomy
Increase in the Use of Adjuvant Chemoradiotherapy Following the Report of the Intergroup 0116 Trial
Cost-Effectiveness of Adjuvant Chemoradiotherapy in Gastric Cancer
Concluding Remarks

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.